Patrick Frayssinet

World Vaccine Congress Washington Speaker Interview: Dr Patrick Frayssinet

|| Dr Patrick Frayssinet, R&D Director, URODELIA We have interviewed a few of the speakers from World Vaccine Congress Washington, taking place on 10-12 April 2017 in Grand Hyatt Washington. This is the 1st of the interview series, stay connected for more. Q1: The most promise opportunities in the veterinary vaccines space are? A: One of the most promise opportunities …

ViE Awards 2016 – Voting is now open!

After weeks of voting and over 1000 nominations collected, we are happy to announce the highly nominated companies in each category as voted by you and your peers for the 9th annual Vaccine Industry Excellence (ViE) Awards in the following categories Best Clinical Trial Site AND Network Best Contract Research Organization Best Contract Manufacturing Organization Best Production/Process Development  Best Academic Research Team …

Over 600 Vaccine executives confirmed!

In terms of the attendees you will meet at the World Vaccine Congress Washington next month, with weeks to go the event is tracking well ahead of this same point last year. In fact we are estimating a growth in numbers by about 25% overall bringing well over 600 leading vaccine executives to the congress. This means by attending you …

Retroscreen Virology Senior Medical Director to speak at World Vaccine Congress USA 2015

The world’s leading research company in human viral challenge models, Retroscreen Virology, has announced one of its scientific and medical leadership team will be speaking at 2015 World Vaccine Congress in the USA. Dr Martin Johnson, Senior Medical Director at Retroscreen Virology, is going to be talking about the Retroscreen hVIVO human viral challenge model and how it can be …

Geographical risk of Dengue and clinical studies conducted by Sanofi Pasteur

Making Dengue the Next Vaccine-Preventable Disease

Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.   In 2013, the WHO ranked …